Alcohol - problem drinking
Exam Tips
- Know UK units: units = volume (mL) x ABV (%) / 1000; 125 mL wine at 12% ABV is 1.5 units.
- In OSCEs, classify use as hazardous, harmful, or dependent and quantify weekly units before advising.
- Always assess withdrawal risk and red flags (seizures, delirium tremens, confusion/ataxia/eye signs).
- High-yield safety point: in at-risk drinkers, give thiamine promptly and treat suspected Wernicke encephalopathy with parenteral therapy.
- For prescribing stations, remember relapse-prevention options and key contraindications (renal function for acamprosate, opioid use/liver status for naltrexone, severe disulfiram reaction risk).
Definition
Problem drinking is alcohol consumption above the UK low-risk threshold, with increased risk generally starting above 14 units/week in both men and women. It spans hazardous use, harmful use (where alcohol is already causing physical or psychological harm), and alcohol dependence, which is marked by craving, tolerance, withdrawal, and continued use despite clear adverse consequences.
Pathophysiology
Alcohol-use disorder reflects progressive neuroadaptation and behavioural reinforcement. Acutely, ethanol enhances inhibitory GABA-A signalling and suppresses excitatory glutamate (including NMDA) pathways; chronic exposure causes receptor-level adaptation (reduced inhibitory tone and increased excitatory drive), so abrupt reduction triggers autonomic and neuropsychiatric withdrawal symptoms. Mesolimbic dopamine reward pathways reinforce repeated use, while chronic exposure shifts from impulsive reward-seeking to compulsive drinking driven by avoidance of withdrawal and negative affect. Systemic toxicity contributes to end-organ injury (hepatic steatosis/hepatitis/cirrhosis, pancreatitis, cardiomyopathy), and nutritional deficiency (especially thiamine deficiency) underpins Wernicke-Korsakoff syndromes. See Figure: alcohol withdrawal timeline and neuroadaptation model.
Risk Factors
- Regular intake above 14 units/week (risk rises further at >35 units/week in women and >50 units/week in men)
- Previous harmful drinking or prior withdrawal/detox episodes
- Comorbid mental illness (for example depression, anxiety, psychosis, personality disorder)
- Family history of alcohol-use disorder and early age of first heavy use
- Social stressors: unemployment, housing instability, relationship breakdown, trauma
- Concurrent substance misuse (including benzodiazepines or opioids)
- Male sex shows higher recorded rates, but harmful use in women is often under-recognized
- Pregnancy exposure risk due to fetal vulnerability (FASD risk)
Clinical Features
Symptoms
- Loss of control over amount or duration of drinking
- Craving and persistent unsuccessful attempts to cut down
- Tolerance (needs more alcohol for same effect)
- Withdrawal symptoms when reducing intake: anxiety, sweating, tremor, nausea, insomnia, agitation
- Time spent obtaining/using/recovering from alcohol with neglect of roles and activities
- Continued drinking despite depression, accidents, pancreatitis, liver disease, or interpersonal harm
- Blackouts, memory impairment, or morning drinking to relieve withdrawal
- In pregnancy: concern about fetal effects after ongoing alcohol intake
Signs
- Alcohol odour, slurred speech, ataxia, impaired coordination in intoxication
- Fine tremor, tachycardia, hypertension, diaphoresis in withdrawal
- Hepatomegaly, stigmata of chronic liver disease (spider naevi, palmar erythema, jaundice)
- Peripheral neuropathy, proximal myopathy, cognitive change
- Features of Wernicke encephalopathy: confusion, ataxia, ophthalmoplegia/nystagmus
- Signs of complications such as epigastric tenderness (pancreatitis) or arrhythmia/cardiomyopathy
Investigations
Management
Lifestyle Modifications
- Deliver brief intervention in primary care (structured advice, motivational interviewing, goal setting, planned review)
- Use UK unit-based harm-reduction targets; if drinking up to 14 units/week, advise spreading over at least 3 days and including alcohol-free days
- Advise complete abstinence in pregnancy or when dependence/advanced liver disease is present
- Offer psychosocial treatment (CBT-based relapse prevention, social support, family involvement, mutual-aid groups)
- Assess safeguarding risk, self-harm/suicide risk, driving safety, and occupational risk
- Nutritional support and vitamin replacement, especially in malnutrition
Pharmacological Treatment
Vitamin replacement (prevention/treatment of thiamine deficiency)
- Thiamine oral 100 mg two to three times daily
- Pabrinex (IV high-potency B vitamins): 2 pairs of ampoules three times daily for suspected Wernicke encephalopathy, then 1 pair daily for 3-5 days if improving
Give parenteral thiamine urgently when Wernicke encephalopathy is suspected; do not delay thiamine in at-risk patients. Continue oral thiamine after acute treatment.
Assisted alcohol withdrawal
- Chlordiazepoxide oral, typically 10-30 mg four times daily initially, then taper over about 5-10 days (individualized regimen)
Use symptom-triggered or fixed-dose protocol with close monitoring. Caution in severe liver impairment, respiratory disease, and older/frail adults due to sedation and falls risk.
Relapse prevention after detox/abstinence plan
- Acamprosate 666 mg three times daily (if body weight <60 kg: 666 mg morning, 333 mg midday, 333 mg evening)
- Naltrexone 50 mg once daily
- Disulfiram 200 mg once daily (usual range 100-500 mg daily)
Acamprosate is contraindicated in severe renal impairment. Naltrexone is contraindicated in current opioid use/dependence and acute hepatitis; check LFTs and opioid status first. Disulfiram can cause severe alcohol-disulfiram reaction; avoid in significant cardiac disease, psychosis, and pregnancy, and ensure informed consent/supervision.
Complications
- Accidents, injury, drowning, self-harm, and alcohol poisoning
- Alcohol-related cancers (including oral cavity, pharyngeal, oesophageal, liver, bowel, and breast)
- Hypertension, arrhythmia, and alcoholic cardiomyopathy with heart failure/stroke risk
- Alcohol-related liver disease: steatosis, alcoholic hepatitis, cirrhosis, variceal bleeding, hepatic failure
- Acute and chronic pancreatitis, with malabsorption and diabetes in chronic disease
- Psychiatric morbidity including depression, anxiety, suicidality, and social deterioration
- Wernicke encephalopathy progressing to Korsakoff syndrome if undertreated
- Fetal alcohol spectrum disorder, miscarriage, stillbirth, and preterm birth with prenatal exposure
Prognosis
Brief intervention can significantly reduce intake in hazardous/harmful drinkers, but alcohol dependence is commonly chronic and relapse is frequent, especially in the first year after treatment initiation. Outcomes improve with sustained psychosocial support, relapse-prevention medication, and early management of comorbidity; untreated severe AUD carries substantial long-term morbidity and premature mortality.
Sources & References
✅NICE Guidelines(1)
- Alcohol - problem drinking[overview]
📖Textbook References(1)
- David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 1832)[context]